Boston Scientific target raised, added to ‘Tactical Outperform’ list at Evercore

Evercore ISI raised the firm’s price target on Boston Scientific (BSX) to $90 from $82 and keeps an Outperform rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends for are on track for improvement in the second half, but the debate is around the instrument outlook and China stimulus given the recent run in stocks in the space, the analyst tells investors in MedTech and Tools Q3 preview. Additionally, the analyst is adding Boston Scientific along with several other names in the group to the firm’s “Tactical Outperform” list and keeping Exact Sciences (EXAS) on the list heading into Q3 results.